Loading...

MedXY News - GLP-1 receptor agonists

MedXY AI/MedXY News/Tag: GLP-1 receptor agonists

MedXY News

EnglishTag

GLP-1 receptor agonists

40 all articles · 20 / page

Ask MedXY AI

type 2 diabetes clinical trial immunotherapy heart failure obesity atrial fibrillation cardiovascular risk Cardiology biomarkers clinical trials Hypertension oncology public health critical care artificial intelligence breast cancer Alzheimer's disease diabetes cardiovascular disease type 1 diabetes nutrition chronic kidney disease

Latest news

Tag

GLP-1 Receptor Agonists Significantly Reduce Atrial Fibrillation Recurrence and Mortality Following Catheter Ablation in Obese Patients

GLP-1 Receptor Agonists Significantly Reduce Atrial Fibrillation Recurrence and Mortality Following Catheter Ablation in Obese Patients

By MedXY|Feb 4, 2026

This large-scale real-world analysis reveals that GLP-1 receptor agonist therapy reduces atrial fibrillation recurrence by 18% and lowers all-cause mortality in obese patients following catheter ablation, highlighting a potent upstream stra

GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

By MedXY|Feb 4, 2026

This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a

GLP-1 Receptor Agonists Significantly Reduce MACE Risk Across the CKD Spectrum, Yet Prescription Rates Remain Suboptimal

Diabetes & Endocrinology

GLP-1 Receptor Agonists Significantly Reduce MACE Risk Across the CKD Spectrum, Yet Prescription Rates Remain Suboptimal

By MedXY|Feb 3, 2026

Recent data highlights that GLP-1 receptor agonists (GLP1-RAs) reduce cardiovascular risk in patients with chronic kidney disease (CKD), yet real-world prescription rates remain alarmingly low despite these proven benefits across various st

Mind the Gap: Patients with Mental Disorders Face Significant Disparities in Diabetes Monitoring and Modern Therapies

Diabetes & Endocrinology

Mind the Gap: Patients with Mental Disorders Face Significant Disparities in Diabetes Monitoring and Modern Therapies

By MedXY|Jan 30, 2026

A massive systematic review of 5.5 million patients reveals that those with mental disorders receive significantly lower quality diabetes care, including less frequent monitoring and a 74% lower likelihood of being prescribed GLP-1 receptor

SGLT2 Inhibitors Edge Out GLP-1 RAs in Kidney Protection: Insights from a Target Trial Emulation

Diabetes & Endocrinology

SGLT2 Inhibitors Edge Out GLP-1 RAs in Kidney Protection: Insights from a Target Trial Emulation

By MedXY|Jan 26, 2026

A nationwide Danish study suggests SGLT2 inhibitors offer superior protection against chronic kidney disease and acute kidney injury compared to GLP-1 receptor agonists in patients with type 2 diabetes, particularly for primary prevention.

GLP-1 Receptor Agonists Associated with Significantly Lower Risk of Subarachnoid Hemorrhage in Patients with Intracranial Aneurysms

Diabetes & Endocrinology

GLP-1 Receptor Agonists Associated with Significantly Lower Risk of Subarachnoid Hemorrhage in Patients with Intracranial Aneurysms

By MedXY|Jan 7, 2026

A large-scale retrospective cohort study reveals that GLP-1 receptor agonists reduce the risk of subarachnoid hemorrhage by 34% and all-cause mortality by 37% in patients with type 2 diabetes and intracranial aneurysms, suggesting a potent

Semaglutide Extends Survival in Non-Overweight Type 2 Diabetes Patients: New Evidence Challenges BMI-Centric Treatment Models

Semaglutide Extends Survival in Non-Overweight Type 2 Diabetes Patients: New Evidence Challenges BMI-Centric Treatment Models

By MedXY|Jan 5, 2026

A large-scale retrospective study demonstrates that semaglutide reduces all-cause mortality by 46% in non-overweight patients with Type 2 diabetes compared to DPP-4 inhibitors, highlighting cardioprotective benefits independent of weight re

Beyond Glucose: SGLT-2 Inhibitors and GLP-1 Receptor Agonists Slow Frailty Progression in Older Adults

Diabetes & Endocrinology

Beyond Glucose: SGLT-2 Inhibitors and GLP-1 Receptor Agonists Slow Frailty Progression in Older Adults

By MedXY|Dec 31, 2025

A large-scale Medicare study suggests that SGLT-2 inhibitors and GLP-1 receptor agonists significantly slow frailty progression in older adults with type 2 diabetes, independent of their cardiovascular benefits, marking a potential shift in

Beyond the Heart: Why Metabolic Gains Are the True Drivers of GLP-1RA Cardioprotection

Beyond the Heart: Why Metabolic Gains Are the True Drivers of GLP-1RA Cardioprotection

By MedXY|Dec 31, 2025

A robust Mendelian randomization study demonstrates that the reduced risk of myocardial infarction associated with GLP-1 receptor agonists is primarily mediated by improvements in HbA1c, BMI, and lipid profiles, rather than direct cardiac e

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

Diabetes & Endocrinology

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

By MedXY|Nov 1, 2025

This article critically compares the efficacy, safety, and long-term outcomes of tirzepatide, semaglutide, and liraglutide for the treatment of obesity based on recent Cochrane systematic reviews, highlighting differences in weight loss, ad

Glucagon-Like Peptide-1 Receptor Agonists and Ocular Risks: A Comprehensive Review of Neovascular AMD, Diabetic Retinopathy, and Ischemic Optic Neuropathy in Diabetes

Diabetes & Endocrinology

Glucagon-Like Peptide-1 Receptor Agonists and Ocular Risks: A Comprehensive Review of Neovascular AMD, Diabetic Retinopathy, and Ischemic Optic Neuropathy in Diabetes

By MedXY|Oct 29, 2025

GLP-1 receptor agonists used in diabetes show a twofold increased risk of neovascular AMD, a modest risk elevation for diabetic retinopathy, and a small but significant increased risk for nonarteritic anterior ischemic optic neuropathy, war

GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: Emerging Evidence and Clinical Implications

Clinical Updates

GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: Emerging Evidence and Clinical Implications

By MedXY|Oct 28, 2025

GLP-1 receptor agonists show promise in idiopathic intracranial hypertension by reducing symptoms, medication use, surgical interventions, and mortality, independent of significant BMI change, highlighting a novel therapeutic approach warra

Comparative Effectiveness and Costs of Bariatric Surgery Versus GLP-1 Receptor Agonists in Obesity Management

Internal Medicine

Comparative Effectiveness and Costs of Bariatric Surgery Versus GLP-1 Receptor Agonists in Obesity Management

By MedXY|Oct 27, 2025

This article reviews recent evidence comparing weight loss outcomes and healthcare costs of bariatric surgery and GLP-1 receptor agonists, highlighting implications for clinical decision-making in treating class II and III obesity.

Glucagon-Like Peptide-1 Receptor Agonists May Lower the Risk of Nonexudative Age-Related Macular Degeneration in Obese Non-Diabetic Adults

Diabetes & Endocrinology

Glucagon-Like Peptide-1 Receptor Agonists May Lower the Risk of Nonexudative Age-Related Macular Degeneration in Obese Non-Diabetic Adults

By MedXY|Oct 26, 2025

A large retrospective cohort study reveals that GLP-1 receptor agonists significantly reduce the risk of developing nonexudative age-related macular degeneration in obese individuals without diabetes, with no effect on progression to exudat

Patterns and Predictors of GLP-1 Agonist Use After Bariatric Surgery in US Adults

Diabetes & Endocrinology

Patterns and Predictors of GLP-1 Agonist Use After Bariatric Surgery in US Adults

By MedXY|Oct 10, 2025

A large US cohort study reveals that 14% of bariatric surgery patients start GLP-1 receptor agonists postoperatively, with higher use seen among women, sleeve gastrectomy recipients, and those with greater BMI regain.

Promising Links Between Diabetes Medications and Alzheimer’s Disease Risk Reduction

Clinical Updates

Promising Links Between Diabetes Medications and Alzheimer’s Disease Risk Reduction

By MedXY|Oct 9, 2025

Recent real-world data suggest GLP-1 receptor agonists and SGLT2 inhibitors may lower Alzheimer’s disease risk more effectively than DPP-4 inhibitors, highlighting the need for randomized trials to confirm potential neuroprotective benefits

Injectable GLP-1 Use Soars Among US Adults with Diabetes: Trends and Clinical Implications

Clinical Updates

Injectable GLP-1 Use Soars Among US Adults with Diabetes: Trends and Clinical Implications

By MedXY|Oct 7, 2025

Nearly 1 in 4 US adults with diabetes used injectable GLP-1 receptor agonists in 2024, reflecting rising adoption for glycemic control and obesity management with notable demographic disparities.

GLP-1 Receptor Agonists in Obesity: Emerging Evidence for Cancer Risk Modulation

Clinical Updates

GLP-1 Receptor Agonists in Obesity: Emerging Evidence for Cancer Risk Modulation

By MedXY|Aug 31, 2025

GLP-1 receptor agonists, used for obesity and type 2 diabetes management, are linked to a 17% lower overall cancer risk, notably hormone-sensitive cancers, but may increase kidney cancer risk. Further research is needed to clarify safety an

Enhancing Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes: Insights from Dapagliflozin and Exenatide Combination Therapy

Clinical Updates

Enhancing Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes: Insights from Dapagliflozin and Exenatide Combination Therapy

By MedXY|Oct 5, 2025

Dapagliflozin and exenatide independently improve beta-cell function and insulin sensitivity in type 2 diabetes; their combination markedly enhances these effects, suggesting superior glycemic control potential.

GLP-1 Receptor Agonists and Dementia Risk in Older Adults With Type 2 Diabetes: Insights From a Target Trial Emulation

Clinical Updates

GLP-1 Receptor Agonists and Dementia Risk in Older Adults With Type 2 Diabetes: Insights From a Target Trial Emulation

By MedXY|Oct 1, 2025

A large-scale emulated trial found no clear overall reduction in dementia risk with GLP-1 receptor agonists versus DPP-4 inhibitors in older adults with type 2 diabetes, though age-specific effects warrant further investigation.

Ask MedXY AI

Most popular

Initiation, Adherence, and Persistence to Guideline-Directed Medical Therapy After Heart Failure Hospitalization: Bridging the Gap Between Prescription and Sustained Use

Family Medicine & Nutrition

How Often Should Men Have Sex? Harvard Study Links 21 Times a Month to Lower Prostate Cancer Risk

SSRIs vs. Second-Generation Antipsychotics for Managing Agitation in Dementia: Real-World Evidence from Nursing Homes

Clinical Updates

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

Olorofim for Poorly Controlled Disseminated Coccidioidomycosis: Phase 2b Clinical Efficacy and Safety Insights